To view or add a comment, sign in Decoding VCT220 (CX11, gimaglipron): China's Oral GLP-1 Contender Alongside Orforglipron and HRS-7535 Following positive Phase 3 topline results in Chinese adults with obesity, VCT220 (Gimaglipron, CX11), discovered by Vincentage Pharma and now being developed globally by CORXEL Pharmaceuticals, has emerged as one of China's leading oral small-molecule GLP-1 receptor agonists, with NDA submission planned for obesity and potential expansion into type 2 diabetes
There is currently no licensed route through which retatrutide can be prescribed or obtained in the UK outside of a clinical trial
In his honor, we are committed to providing clean, functional, and science-backed supplements that help you perform at your best
PubMed:9849822 Andersen, N.B., et al
Enhanced stability and potency for higher antioxidant defense against dark spots and UV damage